Navigation Links
AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

rifosine 50 mg daily or placebo. The Phase 3 trial design is based on positive data reported from the Phase 1/2 trial which was recently reported at the 51st American Society of Hematology meeting.

Patients eligible for the Phase 3 trial must have been previously treated with both bortezomib (Velcade(R)) and an immunomodulatory agent (Revlimid(R) and/or Thalidomid(R)), and been previously treated with one to four prior lines of therapy. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety. Patients can be relapsed from and refractory to all non-bortezomib based therapies, however, patients can only be relapsed (progressed more than 60 days after discontinuing therapy) from prior bortezomib-based therapies. The study is powered at 90% to demonstrate the required difference in progression-free survival between the two arms. Approximately 265 events (defined as disease progression or death) will trigger the un-blinding of the data.

The Company expects a patient recruitment period of approximately 16-18 months, with study completion expected within approximately 20-22 months from today.

About Perifosine (KRX-0401)

Perifosine is a novel oral anticancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. Perifosine is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma for which it has received Orphan Drug and Fast Track designations from the FDA in this indication. Perifosine is also in Phase 2 clinical trials for several other tumor types.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but t
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Announces Appointment of New Board Member
2. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
5. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
6. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
7. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
8. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
9. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... Dennis R. HIll M.D. Radiation Oncologist at the ... recently there has been a promotion of the idea that ... seed, or low dose rate, brachytherapy for prostate cancer. The ... a shorter half life, and gives a higher biologically effective ... has a higher average energy than the other commonly used ...
(Date:5/24/2013)... Dr. Ingrid Warmuth and Anamaria Newport, MHS, ... proud to announce an Open House at their Swedesboro location, ... June 8th from 10 AM to 2 PM. , ... and staff will be on hand to talk to people ... and provide complimentary cosmetic consultations. There will also be specials ...
(Date:5/24/2013)... Bellingham, WA (PRWEB) May 24, 2013 ... researchers, engineers, and industry suppliers will present technologies ... life at the annual SPIE Optics and ... August. Organized by SPIE, the international society ... the largest international, multidisciplinary optical sciences and technology ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Bed bug cases ... protect themselves from the looming higher risk of becoming the ... a new bed bug guideline. In the guide, the company ... and avoiding them while traveling. , According to ... an increase of bed bug infestation during summer: the warm ...
Breaking Biology Technology:Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 2Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3
... US Oncology, Inc . today announced that ... service, has exceeded the $15 million mark and has assisted more ... the launch of Care Advantage in August 2006. , , ... a positive resource to help so many cancer patients obtain lifesaving ...
... PLYMOUTH, Mass., July 9 Harvest Technologies Corp. ( ... sponsored 60-patient clinical trial conducted at Sri Ramachandra Medical ... to treat patients with non-reconstructable Critical Limb Ischemia (CLI) ... is a Harvard Medical international-associated institution based in Chennai, ...
... 9 Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), ... the appointment of Gary A. Lyons, to the Company,s board ... on the Poniard board to ten. , , "We ... us as we move toward our goal of commercializing picoplatin ...
Cached Biology Technology:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance 2OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance 3OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance 4Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors 2Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors 3
(Date:5/24/2013)... complex systems like ecosystems can get messy, especially when ... unknowns like climate change. , In a new ... Proceedings of the National Academy of Sciences , researchers ... fundamental assumption at the very heart of a popular ... model how climate changes may impact biodiversity, researchers like ...
(Date:5/24/2013)... A frequently expressed concern in the ongoing public health ... especially those that are nutrient dense. A new ... Provide Most Nutrients Per Penny," published in the journal ... of the best nutritional values in the produce aisle, ... than most other raw vegetables and delivering one of ...
(Date:5/24/2013)... fastest growing open-access publishers, today announces the launch of ... A broad scope journal covering all specialties, Frontiers ... web platform for the research community to publish high ... and interactive peer-review enables fast, fair and constructive review ... of three months from submission to final decision for ...
Breaking Biology News(10 mins):Understanding the past and predicting the future by looking across space and time 2New research shows that potatoes provide one of the best nutritional values per penny 2Frontiers launches new open-access journal in physics 2Frontiers launches new open-access journal in physics 3
... 2008A study comparing breastfed and formula fed infants across ... are greater than the potential risks associated with infant ... present in breastmilk, according to a report published in ... Breastfeeding Medicine , a peer-reviewed journal published by Mary ...
... ability to view the activity of any chosen gene ... With GeneVision, military commanders could compare gene expression in ... to craving as shoppers moved about a store. "The ... his love-struck dates. Frightening? Perhaps. Ethically suspect? Certainly. ...
... researchers have developed the first natural, nontoxic method ... help diminish the environmental and health concerns that ... materials commonly used in products, from electronics to ... that carbon nanotubes deteriorate when exposed to the ...
Cached Biology News:Benefits of breastfeeding outweigh risk of infant exposure to environmental chemicals in breastmilk 2Real-time gene monitoring developed 2Pitt researchers create non-toxic clean-up method for potentially toxic nano materials 2
Donor feline serum and plasma...
Collected from sexually mature, mixed sex, mixed breed cats. Physiochemical constituents are measured to ensure lot-to-lot consistency....
Complete cell culture media with cytokines...
... available in single head (T2-04 SH) or twin ... portable air and gas applications. Delivering flow up ... environments where DC operation, high performance, low cost, ... Offers ultra-compact size, long life, and high efficiency. ...
Biology Products: